Bio-Rad Laboratories Inc (BIO)

Return on equity (ROE)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	-1,844,202	-778,694	-1,325,609	-322,369	-637,323	-153,537	-424,026	-188,960	-3,627,532	-6,034,686	-1,942,424	-101,126	4,245,898	6,658,660	4,045,450	4,097,765	3,806,263	3,520,647	1,947,011	1,579,392
Total stockholders’ equity	US$ in thousands	6,569,300	7,487,860	6,778,790	9,051,130	8,741,130	8,416,200	8,446,890	9,763,720	9,615,250	8,453,600	8,922,600	10,182,900	13,667,100	15,332,400	11,594,900	10,609,100	9,879,940	8,825,140	7,353,400	6,293,080
ROE		-28.07%	-10.40%	-19.56%	-3.56%	-7.29%	-1.82%	-5.02%	-1.94%	-37.73%	-71.39%	-21.77%	-0.99%	31.07%	43.43%	34.89%	38.63%	38.53%	39.89%	26.48%	25.10%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-1,844,202K ÷ $6,569,300K
= -28.07%

Bio-Rad Laboratories Inc's return on equity (ROE) has exhibited significant fluctuations over the quarters from March 31, 2020, to December 31, 2024. The ROE stood at healthy levels ranging from 25.10% to 43.43% between March 31, 2020, and September 30, 2021, indicating efficient utilization of shareholders' equity to generate profits.

However, starting from March 31, 2022, the ROE experienced a noticeable decline, and by December 31, 2024, it turned negative, indicating that the company's net income was insufficient to cover the equity invested. The negative ROE values from March 31, 2022, to December 31, 2024, may raise concerns about the company's profitability and operational efficiency in utilizing shareholder funds.

Further analysis is required to understand the factors contributing to this significant decrease in ROE and to assess the company's financial health and performance in the upcoming periods.